Analyst Activity – Royal Bank of Canada Raises Its Price Target On ImmunoGen (NASDAQ:IMGN) to

ME Staff
-
0

Analyst Ratings For ImmunoGen (NASDAQ:IMGN)

Today, Royal Bank of Canada raised its price target on ImmunoGen (NASDAQ:IMGN) to per share.

Some recent analyst ratings include

  • 11/3/2017-Cantor Fitzgerald Reiterated Rating of Hold.
  • 10/12/2017-Jefferies Group Reiterated Rating of Buy.
  • 8/30/2017-Canaccord Genuity Reiterated Rating of Buy.
  • 8/29/2017-Cowen Reiterated Rating of Hold.
  • 8/29/2017-Leerink Swann Reiterated Rating of Outperform .

Recent Insider Trading Activity For ImmunoGen (NASDAQ:IMGN)
ImmunoGen (NASDAQ:IMGN) has insider ownership of 6.51% and institutional ownership of 78.25%.

  • On 3/16/2018 Daniel M Junius, Director, sold 25,000 with an average share price of $12.02 per share and the total transaction amounting to $300,500.00.
  • On 3/15/2018 David Brannon Johnston, CFO, sold 10,000 with an average share price of $11.53 per share and the total transaction amounting to $115,300.00.
  • On 2/21/2018 David Brannon Johnston, CFO, sold 21,060 with an average share price of $10.87 per share and the total transaction amounting to $228,922.20.
  • On 2/21/2018 Mark J Enyedy, CEO, sold 67,717 with an average share price of $10.87 per share and the total transaction amounting to $736,083.79.
  • On 2/21/2018 Richard J Gregory, VP, sold 34,486 with an average share price of $10.88 per share and the total transaction amounting to $375,207.68.
  • On 2/20/2018 Daniel M Junius, Director, sold 25,000 with an average share price of $11.68 per share and the total transaction amounting to $292,000.00.
  • On 2/13/2018 Daniel M Junius, Director, sold 46,667 with an average share price of $10.01 per share and the total transaction amounting to $467,136.67.

Recent Trading Activity for ImmunoGen (NASDAQ:IMGN)
Shares of ImmunoGen closed the previous trading session at with shares trading hands.